Further, TEB-17231 exhibited tumor growth inhibition (IC50) in KRAS-G12C Ba/F3 (14 nM) and derivative cell lines that acquired resistance to G12C inhibitor MRTX849….These properties highlight TEB-17231 as a potential clinically actionable inhibitor for the KRAS-modified tumor population